Teva Sued by UCB Over Generic Copy of Epilepsy Drug
Teva Pharmaceutical Industries Ltd. (TEVA), the world’s largest generic-drug maker, was sued for patent infringement by a U.S. unit of UCB SA (UCB) in a bid to block plans to copy the epilepsy drug Vimpat.
UCB, based in Brussels, seeks unspecified damages from Petach Tikva, Israel-based Teva, according to a complaint filed today in federal court in Wilmington, Delaware.
Denise Bradley, a Teva spokeswoman, said in an e-mailed message that the company would have no comment on the lawsuit.
To see the patent, click: RE 38,551.
The case is UCB v. Teva, 13-cv-01148, U.S. District Court, District of Delaware (Wilmington).
To contact the reporter on this story: Phil Milford in Wilmington, Delaware, at email@example.com
To contact the editor responsible for this story: Michael Hytha at firstname.lastname@example.org